IL -13R2 chain, the primary interleukin -13 ( IL -13 ) binding protein, plays an important role in IL -13 binding and internalization. Based on these findings, in our previous study we transiently transfected four cancer cell lines that do not express IL -13R2 chain and demonstrated that these cells acquired increased sensitivity to IL -13 receptor -targeted recombinant cytotoxin, IL13 -PE38QQR, which is composed of IL -13 and a mutated form of a Pseudomonas exotoxin. Although some prostate cancer cell lines express functional IL -13R, they are not highly sensitive to IL -13 cytotoxin. Here we investigated whether human prostate cancer and normal prostate epithelial cell lines express IL -13R2 chain and whether they can be sensitized to the cytotoxic effect of IL -13 cytotoxin after transient or stable gene transfer of IL -13R2 chain. Gene transfer of IL -13R2 chain improved binding activity of IL -13 and sensitivity to IL -13 cytotoxin in vitro. In vivo experiments demonstrated that gene transfer of IL -13R2 chain dramatically enhanced the antitumor activity of IL -13 cytotoxin in human prostate cancer xenograft models. These results suggest that IL -13R -targeted cytotoxin therapy of prostate cancer may be dramatically enhanced by gene transfer of IL -13R2 chain and this strategy, the combination of gene therapy and cytotoxin therapy, may be utilized in the treatment of localized prostate cancer. Cancer Gene Therapy ( 2001 ) 8, 861 -868
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Key words: Interleukin -13 receptor; cytotoxin therapy; gene therapy; prostate cancer; sensitization; Pseudomonas exotoxin. P rostate cancer is the most commonly diagnosed cancer in men in the United States. Approximately 180,400 cases of prostate cancer were diagnosed, and an estimated 31,900 men died from the disease in the year 2000 alone. 1 Despite the improvement in surgery and radiation therapy, advanced androgen -independent prostate cancer remains a clinically challenging disease. 2 New approaches are required for effective treatment of this disease.
Targeting of overexpressed or unique cell surface receptors or antigens with specific cytotoxic agents is a new form of cancer therapy. In this approach, an antibody specific to antigen or receptors or ligand that specifically binds to the receptors are chemically conjugated or genetically fused to bacterial or plant toxins or chemical drugs. 3 -8 These agents are expected to be cytotoxic to cells that overexpress these antigens or receptors without causing collateral damage to normal cells that do not express these targets. The success of this form of therapy depends on the identification of receptors or antigens on tumor cells. In that regard, we have identified overexpression of receptors for an immune regulatory cytokine interleukin -13 (IL -13 ) on human glioblastoma multiforme, AIDS -associated Kaposi's sarcoma, and human renal cell carcinoma cell lines. 9 -14 To target tumor cells that express IL -13 receptors ( IL-13Rs ), a novel cytotoxic agent was developed in which C -terminus of IL -13 was genetically fused to N -terminus of a mutated form of a bacterial toxin, Pseudomonas exotoxin. This cytotoxin termed IL13 -PE38QQR was found to be highly cytotoxic to IL -13R positive tumor cells in vitro and in vivo.
-13
The structure of IL -13Rs has been studied extensively in various cell types. 9,15 -19 It has been reported that IL -13 can bind to two chains of $65 -kDa proteins. The first chain IL-13R1 ( also termed IL -13R or IL -13R 0 ) was cloned in mouse and human systems. 20 -22 Later, an isoform was cloned and termed IL -13R ( later termed IL-13R2) chain. 23 IL -13R1 chain can form a productive complex with IL-4R chain ( also known as IL -4R ) for IL-13 signal transduction. 22, 24 Based on these studies, it has been proposed that IL -13R can exist in at least three different forms. 19, 25 In the first form IL -13 binds to IL -13R2, IL-13R1, and IL -4R chains. In the second form, IL -13 binds to IL -13R1 and IL -4R chains. In this form of IL -13R, IL -13R2 chain is not present. In the third form of IL -13R, IL -2R c ( c ) chain is also present along with IL -13R1 and IL -4R chains. Although c chain can not bind IL -13, it can interfere in IL -13 binding when introduced in cells that naturally do not express this chain. 16 More recently, we have demonstrated that IL -13R2 chain is an essential component in IL -13 binding and internalization. 24, 26 This chain is reported to be expressed in a variety of cancer cell lines; however, some cancer types either do not express or express low levels of this receptor chain. 11 -14 Because of low-level expression of IL -13R2 chain, these cells show no or low sensitivity to IL -13PE38QQR. 10 -13 To demonstrate whether gene transfer of this chain into cancer cells might increase their sensitivity to IL -13 toxin, we transiently transfected IL -13R2 chain into cancer cell lines expressing low levels or no IL -13R2 chain. We found that sensitivity to IL -13 toxin is dramatically increased in transfected cell lines. 26 We previously reported that prostate cancer cell lines, PC -3, DU145, and LNCaP cells express functional IL -13R; however, IL -13 toxin was not very cytotoxic to these cell lines. 27 Based on these results, we hypothesized that the low or no expression of IL-13R binding component IL -13R2 chain on prostate cancer cells may be responsible for the insensitivity to IL -13 toxin. In the current study, we analyzed the subunit structure of IL -13R in five prostate cancer cell lines and two normal prostate epithelial cell lines. None expressed mRNA for IL -13R2 chain. Transient transfection of IL -13R2 chain increased binding affinity to IL -13 and enhanced cytotoxic activity of IL13 -PE38QQR. Furthermore, stable transfection of IL -13R2 chain in a tumorigenic cell line dramatically increased its sensitivity to IL13-PE38QQR in vitro and antitumor activity in an animal model of human prostate cancer.
MATERIALS AND METHODS

Recombinant cytokines and toxin
Recombinant human IL -4 and IL -13 were produced and purified in our laboratory. 28 Recombinant IL13 -PE38QQR in which IL -13 was fused to domains II and III of Pseudomonas exotoxin was also produced and purified in our laboratory ( B. H. Joshi and R. K. Puri, unpublished data ).
Cell lines and culture
Human prostate cancer cell lines ( DU145 and LNCaP ) were purchased from the American Type Culture Collection (Rockville, MD ). Primary normal prostate cell lines ( 568NPTX and 570NP2TX ) and prostate cancer cell lines ( 527CP2TX, 568CP1TX, and 570CP2TX ) were established in Franz Cancer Research Center, Chiles Research Institute (Portland, OR ). 29 Cells were cultured in Eagle's modified essential medium ( EMEM; DU145 ) or RPMI1640 (LNCaP ) containing 10% fetal bovine serum ( FBS; Biowhittaker, Walkersville, MD ), 1 mM HEPES, 1 mM L -glutamine, penicillin ( 100 g/mL ), and streptomycin (100 g/ mL ) ( Biowhittaker ). The other primary cell lines were cultured in keratinocyte serum -free medium ( Keratinocyte -SFM, Life Technologies, Rockville, MD ) containing bovine pituitary extract ( 25 g/ mL ), epidermal growth factor ( 5 ng/mL ), 2 mM L -glutamine, 10 mM HEPES, antibiotics, and 5% FBS.
Transfection and selection
cDNA encoding human IL -13R2 chain 23 was cloned into pME18S mammalian expression vector. 30 Plasmid DNA (12 g /100 -mm culture dish ) was transfected with or without 1.2 g of pPUR selection vector (Clontech Laboratories, Palo Alto, CA ) into semiconfluent cells using GenePORTER transfection reagent ( Gene Therapy Systems, San Diego, CA ) according to the manufacturer's instructions. Briefly, cells ( 2Â10 6 /100 -mm dish ) were incubated with the DNA -GenePORTER mixture for 5 hours in DMEM (Biowhittaker ). Then DMEM containing 20% FBS was added and incubation was continued. Twenty -four hours after transfection, the medium was changed to DMEM with 10% FBS and cells were incubated for an additional 24 hours. About 48 hours after the start of transfection, cells were trypsinized and experiments were performed. For stable transfection, DU145 cells were further cultured in selection medium that contained 1 g /mL of puromycin (Clontech Laboratories ). Cells were maintained for 4 weeks in the same medium, which was replaced every 3 days. Resistant clones isolated with the cloning cylinder (Bel -Art Products, Pequannock, NJ ) were characterized for IL-13R2 chain expression by RT-PCR and radioreceptor binding assays. Finally, IL -13R2 -overexpressing clone ( termed DU1452 ) was selected for further analysis. The vector control -transfected ( mock ) cell line, termed DU145mc, was used for comparison with IL -13R2-transfected cells. To reduce antibiotic side effects on cell behavior, puromycin was removed at least 14 days before experiments were performed.
RT -PCR analysis
To detect the mRNA expression of IL -13R chains in normal prostate and prostate cancer cells, total RNA was isolated using TRIZOL reagent ( Life Technologies, Grand Island, NY ), then RT-PCR analysis was performed. Two micrograms of total RNA was incubated for 30 minutes at 428C in 20 L reaction buffer containing 10 mM TrisHCl (pH 8.3), 5 mM MgCl 2 , 50 mM KCl, 1 mM each of dNTPs, 1 U / L RNase inhibitor, 2.5 M random hexamer, and 2.5 U / L of MMLV RT ( Perkin -Elmer, Norwalk, CT ). A 10-L aliquot of RT reaction was amplified in 100 -L final volume of PCR mixture containing 10 mM Tris -HCl (pH 8.3 ), 2 mM MgCl 2 , 50 mM KCl, 1 U of AmpliTaq Gold DNA polymerase (Perkin -Elmer ), and 0.1 g of specific primers for either IL -13R2 or IL -13R1 chains. 25 PCR product (30 L ) was run on a 2% agarose gel for UV analysis.
Radioreceptor binding
Recombinant human IL -13 was labeled with 125 I ( Amersham, Arlington Heights, IL ) using IODO -GEN reagent ( Pierce, Rockford, IL ) as previously described. 31 The specific activity of the radiolabeled cytokines was estimated to be 6.0 Ci /g of protein.
For binding experiments, 5Â10 5 cells in 100 L binding buffer ( RPMI 1640 containing 0.2% human serum albumin and 10 mM HEPES ) were incubated with 200 pM 125 I -IL -13 with or without various concen-trations (10 pM to 100 nM ) of unlabeled IL -4 or IL-13 at 48C for 2 hours. Cell -bound 125 I -IL -13 was separated from unbound by centrifugation through a phthalate oil gradient and radioactivity was determined with a gamma counter ( Wallac, Gaithersburg, MD ). In some experiments, the number of IL-13Rs and binding affinities were calculated using the LIGAND program. 32 
Protein synthesis inhibition assay
The cytotoxic activity of IL -13 toxin was tested as previously described. 33 Typically, 10 4 cells were cultured in leucine -free medium with or without various concentrations of IL13 -PE38QQR for 20-22 hours at 378C. Then 1 Ci of [ 3 H ]leucine (NEN Research Products, Boston, MA ) was added to each well and incubated for an additional 4 hours. Cells were harvested and radioactivity incorporated into cells was measured by a plate counter (Wallac ). The concentration of IL -13 toxin at which 50% inhibition of protein synthesis (IC 50 ) occurred was calculated.
Animals
Athymic nude mice 4 weeks old (about 20 g in body weight ) were obtained from Frederick Cancer Center Animal Facilities (National Cancer Institute, Frederick, MD ). The mice were housed in filter -top cages in a laminar flow hood in pathogen-free conditions with 12 hours light /12 hours dark cycles. Animal care was in accordance with the guidelines of NIH Animal Research Advisory Committee.
Human prostate cancer xenograft and treatment
A human prostate cancer model was established in nude mice by subcutaneous injection of 4Â10 6 DU145 cells in 150 L of PBS plus 0.2% human serum albumin into the right flank. Palpable tumors developed within 3 -4 days. The mice then received injections of excipient (0.2% human serum albumin in PBS ) or chimeric toxin either intraperitoneally (i.p.; 500 l) or intratumorally (i.t.; 30 l) using a 27 -gauge needle.
Statistical analysis
Tumor sizes were calculated by multiplying length and width of tumors on a given day. The statistical significance of tumor regression was calculated by Student's t test. Fig 2) . However, when these cells were transfected with IL-13R2 chain, consistent with the expression of mRNA for this chain (Fig 1 ) , the binding activity of 125 I-IL-13 was greatly increased. This binding activity was displaced by an excess of unlabeled IL -13. Because IL -13R and IL -4R share two chains with each other, we also examined whether IL -4 can also displace the IL -13 binding in DU145 cells transfected with IL -13R2 chain. 19, 30 As shown in Figure 2 , IL -4 showed only minimal displacement of 125 I-IL-13 binding. These findings indicate that IL -13R2 chaintransfected cells, DU1452 form type I IL -13Rs. 9, 19, 25, 30 To further characterize the IL -13R in IL-13R2 chain -transfected cells, we performed Scatchard analysis on DU1452 cells (Fig 2, b and c ) . DU1452 cells bound IL -13 in a concentration -dependent manner. Scatchard analysis of the binding data showed a single binding site receptor with a K d value of 1.69± 0.4 nM. The number of IL -13Rs was calculated as 15,600± 550 IL -13 molecules bound per cell ( mean ± SD, n =2 ). Because IL -13 binding sites on vector only transfected DU145 cells were calculated to be 30 ± 5 per cell; the increase in IL -13 binding sites in IL -13R2 chain transfectants was 520-fold higher compared with control cells.
RESULTS
IL-13R mRNA expression on prostate cancer cells
Prostate cancer cells transfected with IL -13R2 chain dramatically increased sensitivity to IL -13 toxin
We have produced a chimeric protein composed of IL-13 and a truncated form of Pseudomonas exotoxin ( IL13 -PE38QQR ), which was found to be potently cytotoxic to IL-13R -positive solid tumor cells. [10] [11] [12] [13] To determine whether We also transiently transfected four prostate cancer cell lines and two normal prostate cell lines with IL -13R2 chain and cytotoxic activity of IL-13 toxin was assessed. As shown in Figure 4 , transfection of IL -13R2 chain improved sensitivity to IL-13 toxin in all of the cell lines examined. Although the improvement in IC 50 was not as dramatic as compared with stably transfected DU1452 cell line ( Fig 3) . More than 10 -fold to 1000 -fold increase in IC 50 s were observed. Of note, even the normal prostate cell lines ( 560NPTX and 570NP2TX ) can be sensitized to the 
Antitumor activity of IL -13 toxin to prostate cancer dramatically enhances after gene transfer of IL-13R2 chain
We found that transfection of IL -13R2 chain improved the sensitivity of prostate cancer cell lines to the cytotoxic effect of IL -13 toxin. To explore whether our findings could be applied to an in vivo tumor model, we injected nude mice with subcutaneously growing DU145 tumors i.p. with IL13-PE38QQR. As shown in Figure 5a , DU145mc tumor cells formed a rapidly growing tumor in nude mice. Animals treated with IL -13 toxin (50 g /kg ) twice daily for 5 days ( total 10 injections ) from day 6 to day 10 showed no antitumor efficacy as measured by tumor size over a 60-day period. On day 60, mice in both groups ( n= 5 ) were sacrificed due to large tumor burden.
However, when animals with DU145 tumors transfected with IL-13R2 chain ( DU1452) were treated with IL-13 toxin ( 50 g/ kg) on the same schedule ( twice daily for 5 days), four of five mice showed complete regression by day 11 (Fig 5b ) . By day 22, palpable tumors recurred in all KAWAKAMI, HUSAIN, BRIGHT, ET AL: SENSITIZATION TO IL -13 CYTOTOXIN THERAPY of these mice; however, the size of tumors remained significantly smaller compared to the excipient injected mice ( P <.0002). The average size of the tumors remained smaller than the size before injection until day 43 (27 mm 2 ). On day 60, the size in the treated group was 68% less compared to excipient injected group mice.
Complete regression of IL -13R2 chain gene transferred prostate tumors by intratumoral administration of IL-13 toxin
We have previously observed that availability of drug at the tumor site is of paramount importance in treating tumors in mice. To achieve a higher accumulation of drug, IL -13 toxin was directly injected into the tumor bed. 13 As expected, there were more complete responders with intratumoral injection of IL13-PE38QQR into IL -13R2 gene transferred prostate cancer, DU1452 tumors (Fig 6 ) compared to i.p. injected tumor groups ( Fig 5) . After three injections of IL -13 toxin ( 250 g/ kg per day on alternate days beginning on day 3 ), two of four tumors disappeared completely by day 7. By the day of the last injection (day 10 ), 100% of the tumors were completely regressed. Although by day 24 tumors recurred in two mice, two other mice remained tumor free until day 90 ( data not shown ).
Partial responder prostate tumors retain sensitivity to IL-13 toxin
To determine whether DU1452 tumors that recurred in IL13-PE38QQR -treated animals (Fig 5b ) maintained sensitivity to IL -13 toxin, we resected tumors from both i.p. injected vehicle only and IL -13 toxin -treated (50 g/ kg; twice daily for 5 days from day 6 and day 10 ) mice from day 10 and day 60 after the implantation of tumor. Tumors were minced in pieces and digested with a cocktail of 10 g/ mL collagenase, 1 mg /mL hyaluronidase, and 0.5 mg /mL DNAse ( Sigma Chemical, St. Louis, MO ). Tumor cells were cultured in EMEM medium containing 10% FBS. After three passages, cell debris and contaminating blood cells were removed, and cells were assessed for sensitivity to IL-13 toxin. As shown in Figure 7 , all of the cell lines maintained sensitivity to IL -13 toxin. The IC 50 in all four tumor cells remained close to the IC 50 (4 ± 0.5 ng /mL ) of the transfected cell line injected to establish tumors. 
DISCUSSION
We demonstrate here the proof of principle that gene transfer of IL -13R2 chain gene into low level or no IL -13R2 chain expressing prostate tumor cells dramatically sensitized the cells toward IL -13R -targeted cytotoxin in vitro and in vivo.
It is noteworthy that after gene transfer of IL-13R2 chain into prostate cancer cell lines as well as normal prostate cell lines an enhancement to the cytotoxic activity to IL -13 toxin was observed. This observation suggests that the activity of IL -13 toxin was specific to cells that express IL -13R2 chain. When cells were stably transfected with IL -13R2 chain, for example DU1452, the expression of IL -13R binding sites and cytotoxic activity of IL-13 toxin was dramatically increased. We could further translate these in vitro results into an in vivo DU1452 xenograft model. A dramatic increase in the antitumor activity of IL -13 toxin was achieved. A 68% reduction in tumor size was observed after i.p. treatment with IL -13 toxin. Because IL -13 toxin, IL13 -PE38QQR, is found to be specific to IL -13R -expressing cancer cells and not to human T and B cells, monocytes, normal endothelial cells, and resting or growth factor-activated bone marrow cells that do not express IL -13R2 chain, 11, 25 our current novel findings offer wide possibilities for the utilization of IL -13 toxin in otherwise insensitive prostate cancers.
We have found that various tumor cell lines including renal cell carcinoma, glioblastoma, and AIDS -associated Kaposi's sarcoma express high levels of receptors for IL -13.
10 -14 These receptors were found to be a novel target for IL -13R -targeted cytotoxin therapy. Although prostate cancer cells express functional IL -13R, their potential as a target for IL -13R -targeted cytotoxin therapy was not initially promising. The gene transfer of one subunit of cytokine receptor chain into prostate cancer cells dramatically increased their sensitivity to IL -13 toxin. We believe our findings can be developed into a combination strategy where gene therapy and cytotoxin therapy meet. To further improve our strategy and simulate clinical applications, we are currently examining the antitumor activity of IL13-PE38QQR after direct intratumor gene transfer of IL -13R2 chain in a prostate cancer xenografted nude mouse model.
In the past several years, investigations have focused on new approaches where cancer cells have been sensitized to cytotoxic compounds that are otherwise benign prodrug, after gene transfer of an enzyme that has no direct effects on cellular function. This enzyme expression confers toxicity to an otherwise benign compound that brings about cell death. In one approach, gene transfer for herpes simplex virus thymidine kinase ( HSV-tk ) gene into cancer cells and normal cells followed by treatment with the antiherpes drugs acyclovir or ganciclovir was tested that lead to selective cell death of transduced cells in vitro and in vivo. 34 In another approach, a bacterial and fungal enzyme cytosine deaminase ( CDA ) that catalyzes hydrolytic deamination of cytosine to uracil was introduced into cancer cells. Cells that express CDA convert 5 -fluorocytocine (5 -FC ), a fungicidal and bactericidal drug, to 5 -fluorouracil (5 -FU ), which is then phosphorylated and subsequently inhibits gene transcription resulting in cell death. 35 Although animal models have shown remarkable antitumor activity, disappointing clinical results were observed in a phase I clinical trial using the HSV-tk approach for the treatment of malignant glioma. 36 The lack of successful translation of preclinical results into clinical medicine may be due to poor transfection /gene transfer of enzymes into tumor cells in vivo. In most studies the viral vectors utilized had limited distribution within the tumor bed even after intratumoral administration. 36 It is possible that the in vivo gene transfer of IL -13R2 chain could have a similar disappointing fate in the clinic. However, we will be testing an approach in which the plasmid will be encapsulated into liposomes for better distribution and gene transfer within the tumor bed resulting in IL -13 toxin sensitive tumors. Alternatively, tissue specific promoters will be inserted into vectors that will only direct IL -13R2 gene expression in specific organ with tumor and consequently cell death after IL -13 cytotoxin therapy. Finally, as IL -13R are present in low levels on prostate cancer cells, it is possible that IL -13R can be up -regulated by commonly used pharmacological agents (e.g., steroids and cytokines ) thus avoiding in vivo gene transfer. These approaches are currently being examined in our laboratory.
